drugset / Trial / NCT02975843

Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD Patients

NCT02975843

Phase 1 Completed 28 enrolled Chiesi Farmaceutici S.p.A.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the lung deposition and distribution pattern of Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide using a Gamma-scintigraphic technique after inhalation of a single dose of 99mTc radiolabelled CHF 5993 Administered via pMDI in healthy volunteers, asthmatic and COPD patients.

Timeline

Start
2016-11-21
Primary completion
2017-03-21
Completion
2017-04-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Formoterol Other / unclassified 24 ug Inhaled
Subject Glycopyrronium Unknown 50 ug Inhaled
Subject beclomethasone dipropionate Other / unclassified 400 ug Inhaled